Plasma protein binding of drugs in pregnancy and in neonates.
about
Toxicity of amphetamines: an updateMethods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.All-Purpose Containers? Lipid-Binding Protein - Drug InteractionsPharmacokinetics of clindamycin in pregnant women in the peripartum period.Lopinavir protein binding in HIV-1-infected pregnant women.Human alpha-1-glycoprotein and its interactions with drugs.Protein binding of propranolol and verapamil enantiomers in maternal and foetal serumThe excretion of zopiclone into breast milkMidazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects.Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.Effects of various arterial infusion solutions on red blood cells in the newborn.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymesAssessment of safety of the major antimalarial drugs.Protein binding predictions in infantsGender-specific differences in the central nervous system's response to anesthesia.Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients.Theoretical pharmacokinetic drug alterations in pediatric celiac disease.Pregnancy-related pharmacokinetic changes.Treatment of multiple sclerosis during pregnancy - safety considerations.Cefazolin plasma protein binding and its covariates in neonates.Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.Effects of pronounced haemodilution on the plasma protein binding of lidocaine.
P2860
Q22252794-5C59DA88-1B86-417A-BA75-AA3B0395C72DQ24814147-AE27BCC0-26A4-4B51-BB68-47572F0B94AEQ28546452-5B75BF91-E41D-4EB8-9325-47AAD4A7F380Q33826411-F7D4DE44-5E2A-4611-902C-CB50EEAAE89DQ33869395-CE338AC1-C3A9-43CD-86EB-D2DA43FB3D05Q34331335-86571F23-75F8-44BB-8681-580CD7406FCFQ34346873-BCAF7B42-CCFE-48AF-A52C-4DA2F94FF6E3Q34357569-7404A27F-8710-4065-B8F9-D389002FA538Q34357791-CFD782FD-63A1-41A2-9B15-A0049A71AACCQ34511184-B8BB842C-7A6B-4D9B-BDF6-EEF0F6BCC8B5Q35289967-773C4EF2-C195-401C-A3F7-84A70FA4AFB0Q35689226-98447DCB-61C2-4C54-9BED-E3FA902A229EQ36025069-6253CCBA-8F31-4A8F-B6A1-8D0E72867222Q36216479-BBF1C6BA-D420-4938-8ABE-8CA5A93A9BC5Q36411181-E7759B9A-000C-4181-926E-794277C7FF00Q36763160-93904C4F-CE14-4E0F-A76B-BD3060B2BD19Q36939547-734445D9-76EC-468E-BB60-0D835D04E32EQ36945007-5038C039-73A5-4A41-9348-9E132CF414B1Q37361786-B700DEFC-B7AF-4A0F-A223-B5BC4E6EF0E5Q38170002-956306B2-AA68-4F3A-A81F-0F874B78851EQ38534443-27C25DC4-ABAD-4087-9C20-5410E35E022DQ38544086-36BDF744-CABE-4E15-822F-B2C306D4D73FQ38809225-34EDDE83-C036-4B29-9BB5-0E71CF3DB447Q38883520-C1C4AEEC-1234-43B8-BB53-056703C1019DQ39579691-583489C8-C9DC-467C-BB04-A30BB24AFE57Q39759988-B376B10B-D543-4A3E-BA0F-F8EE99092CA0Q41041971-D766EFFE-5EC3-4B3D-A77A-56DE21270E74Q46345016-6744ADDF-907C-4825-AD66-4CD7767B07C0Q47553402-27189C1C-65E6-41CF-AA6F-70F77C9B9CCFQ47963328-A625AC29-E396-4627-9B14-5D49EB444A1BQ50691157-B7EBE01E-416B-454B-A5A6-BB8B23CAC6ADQ51615171-BC97FF75-3A83-4AF1-B127-52A68892A91F
P2860
Plasma protein binding of drugs in pregnancy and in neonates.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Plasma protein binding of drugs in pregnancy and in neonates.
@en
Plasma protein binding of drugs in pregnancy and in neonates.
@nl
type
label
Plasma protein binding of drugs in pregnancy and in neonates.
@en
Plasma protein binding of drugs in pregnancy and in neonates.
@nl
prefLabel
Plasma protein binding of drugs in pregnancy and in neonates.
@en
Plasma protein binding of drugs in pregnancy and in neonates.
@nl
P1476
Plasma protein binding of drugs in pregnancy and in neonates.
@en
P2093
Notarianni LJ
P356
10.2165/00003088-199018010-00002
P577
1990-01-01T00:00:00Z
P6179
1039392669